Efficacy, safety and albuminuria‐reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12‐week, double‐blind randomized study (the GUARD Study)
暂无分享,去创建一个
D. Cha | K. Oh | Sung Gyun Kim | K. Jeong | Shin-Wook Kang | H. Park | Nam-Ho Kim | S. Yoon | S. Han | K. Na | B. Han | Young-Il Jo | S. Kang | S. H. Park | Y. H. Jang | Seonghye Shin | S. G. Kim